Table 1B:
Characteristics of the subgroup of alcoholic hepatitis patients for the mycobiome analysis
| Treatment at admission | Histology | ||||
| Steroids, n (%), n=58 | 20 (34) | Lobular fibrosis, n=34 | 0 | 2 (5.9) | |
| Pentoxifylline, n (%), n=57 | 7 (12) | 1 | 5 (14.7) | ||
| Steroids and pentoxifylline, n (%), n=58 | 1 (1.7) | 2 | 2 (5.9) | ||
| Antibiotics, n (%), n=58 | 15 (25.9) | 3 | 25 (73.5) | ||
| Prophylactic antibiotics, n (%), n=58 | 12 (20.7) | Pericellular fibrosis, n=35 | 0 | 4 (11.4) | |
| Proton pump inhibitors, n (%), n=28 | 2 (7) | 1 | 31 (88.6) | ||
| Antifungals n (%), n=28 | 0 (0) | Grade of steatosis, n=36 | 1 | 12 (33.3) | |
| 2 | 11 (30.6) | ||||
| Clinical characteristics | 3 | 13 (36.1) | |||
| Infection at admission, n (%), n=53 | 9 (17) | Mallory bodies, n=34 | 0 | 6 (17.6) | |
| Fungal infection (C. albicans), n=53 | 1 (1.9) | 1 | 28 (82.4) | ||
| Ascites | Bilirubinostasis, n=34 | 0 | 13 (38.2) | ||
| No | 17 (29) | 1 | 14 (41.2) | ||
| Small | 28 (47) | 2 | 0 (0.0) | ||
| Large | 14 (24) | 3 | 7 (20.6) | ||
| Ballooning, n=35 | 0 | 22 (62.9) | |||
| Clinical scores and outcome | 1 | 13 (37.1) | |||
| Model for end-stage liver disease (MELD), n=58 | 24 (12-40) | Giant mitochondria, n=31 | 0 | 28 (90.3) | |
| MELD>21, n (%), n=58 | 46 (79) | 1 | 3 (9.7) | ||
| Maddrey’s DF, n=46 | 50 (15-230) | PMN infiltration, n=35 | 0 | 6 (17.1) | |
| Maddrey’s DF >32, n=46 | 40 (87) | 1 | 16 (45.7) | ||
| 30 day mortality rate, n (%), n=56 | 5 (9) | 2 | 13 (37.1) | ||
| 90 day mortality rate, n (%), n=44 | 9 (21) | Inflammatory grade, n=36 | 0 | 12 (33.3) | |
| Follow-up, days, n=56 | 92 (7-762) | 1 | 21 (58.3) | ||
| 2 | 3 (8.3) | ||||
| Histology | |||||
| Liver biopsy available, n (%) | 36 (61) | ||||
| Stage of fibrosis, n=35 | 0 | 1 (2.9) | |||
| 1 | 0 (0.0) | ||||
| 2 | 4 (11.4) | ||||
| 3 | 7 (20.0) | ||||
| 4 | 23 (65.7) | ||||
Clinical characteristics of 59 alcoholic hepatitis patients. Values are presented as median and range in brackets. The number of patients for which the respective data was available is indicated in the first column. Maddrey’s DF, Maddrey’s discriminant function. Fibrosis stage, 0 no fibrosis, 1 portal fibrosis, 2 expansive periportal fibrosis, 3 bridging fibrosis, 4 cirrhosis. Lobular fibrosis, 0 no fibrosis, 1 zone 3 (centrilobular) fibrosis, 2 zone 2+3 (midzonal) fibrosis, 3 panlobular fibrosis. Pericellular fibrosis, 0 absent, 1 present. Steatosis, 1 mild < 33%, 2 moderate < 33-66%, 3 marked > 66%. Mallory bodies, 0 absent, 1 present. Bilirubinostasis, 0 no, 1 hepato-canalicular, 2 cholangiolar, 3 both. Ballooning, 0 occasional hepatocellular, 1 marked hepatocellular, 2 none present. Megamitochondria, 0 absent, 1 present. PMN infiltration, 0 no, 1 mild, 2 severe. Inflammation, 0 no, 1 mild, 2 severe. PMN, polymorphonuclear infiltration.